SCHEMBL16668336

SCHEMBL16668336

N#Cc1cnc(N)cc1OCC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
THRB P10828 1/20 0.46
G6PD P11413 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALOX5AP P20292 3/20 0.39
FEN1 P39748 3/20 0.39
AR P10275 4/20 0.37
FGFR4 P22455 1/20 0.36
AAK1 Q2M2I8 3/20 0.34
MBOAT4 Q96T53 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16668592 0.79 CYP11B1 (0.39) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL23966539 0.79 ALDH1A1 (0.55) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL16668845 0.79 KDM4E (0.43) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL16667846 0.77 FGFR4 (0.40) ALDH1A1KDM4EMEN1USP2KMT2A
SCHEMBL21223618 0.76 ALDH1A1 (0.50) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL16668543 0.75 AAK1 (0.46) ALDH1A1AAK1
SCHEMBL29596850 0.75 XDH (0.44)
SCHEMBL22023311 0.75 XDH (0.44)
SCHEMBL16668617 0.75 SRC (0.44) ARFGFR4
SCHEMBL15878747 0.75 AR (0.53) ALOX5APFEN1ARMBOAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3060563-B1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2018-05-02 EP disclosed
US-9896449-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2018-02-20 US disclosed
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-03-09 US disclosed
US-9533988-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-01-03 US disclosed
EP-3060563-A1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS Novartis AG (CH) 2016-08-31 EP disclosed
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-04-14 US disclosed
US-9266883-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-02-23 US disclosed
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2015-04-30 US disclosed
WO-2015059668-A1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 ALDH1A1 1151/4885MAPT 1361/4885KDM4E 164/4885
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 ALDH1A1 1151/4885MAPT 1361/4885KDM4E 164/4885
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 ALDH1A1 1151/4885MAPT 1361/4885KDM4E 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.